



# SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.

( 深圳市海普瑞藥業集團股份有限公司 )

(A joint stock company incorporated in the People's Republic of China with limited liability)

(於中華人民共和國註冊成立的股份有限公司)

(Stock code 股份代號 : 9989)

## NOTIFICATION LETTER 通知信函

Dear Registered Shareholder (N e 1),

December 18, 2023

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the "Company")

- Notice of publication of Circular, Notice and Proxy Form of the 2024 First Extraordinary General Meeting (the "Current Corporate Communications")

The Board of Directors of the Company has decided to convene a shareholders' meeting to elect the directors of the Company and the HKEx has accepted the Company's application to be listed on the Main Board of the HKEx. The Company has been granted the listing of its shares on the Main Board of the HKEx.

If you are a registered shareholder of the Company, you are invited to attend the meeting. You may request to attend the meeting in person or by proxy. The Request Form (the "Request Form") (which may be downloaded from the website of the Company (http://www.hepalink.com) or the website of the Hong Kong Share Registrar) by the Hong Kong Share Registrar is available for the Request Form (downloaded from the website of the Hong Kong Share Registrar). The address of the Hong Kong Share Registrar is 17/F, Fa Fa Finance Centre, 16 Haxi Road, Hong Kong.

Unless otherwise specified, the Company's website is the primary source of information for the Company's financial statements.

Should you have any queries regarding the above information, please contact the Hong Kong Share Registrar at (852) 2980 1333 from 9:00 am to 6:00 pm, Monday to Friday, excluding public holidays.

Yours faithfully,  
Faded signature  
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.  
Li Li  
Chairman

Note 1: The registered shareholders of the Company are listed in the Circular and the Share Register (CCASS) and the Hong Kong Share Registrar's website. The Company's website is the primary source of information for the Company's financial statements.

Note 2: The Corporate Communications of the Company are available in Chinese and English. The Company's website is the primary source of information for the Company's financial statements.

致非登記股份持有人(附註1):

深圳市海普瑞藥業集團股份有限公司(「本公司」)

- 2024年第一次臨時股東大會通函、通告及代表委任表格(「本次公司通訊文件」)之發佈通知

本公司的本次公司通訊文件中、英文版本現已上載於本公司網站www.hepalink.com及香港交易所披露易網站www.hkex.com.hk，歡迎瀏覽。請在本公司網站主頁的「投資者專區」項下選擇有關文件或在香港交易所披露易網站瀏覽有關文件。

如閣下欲收取本公司本次及將來所有公司通訊文件(附註2)之印刷本，請填妥在本信函背面的申請表格(「申請表格」)(該表格亦可於上述網站下載)，並使用申請表格下方的預付費郵寄標籤寄回(如在香港投寄)；否則，請貼上足夠的郵票。申請表格請經卓佳證券登記有限公司(「香港股份登記處」)寄回本公司，香港股份登記處的地址為香港夏愨道16號遠東金融中心17樓。

